Dendrimers as Drug Carriers for Cancer Therapy
01 Jan 2020-pp 245-269
TL;DR: In this article, the authors describe the application of dendrimers as nanocarriers for drug and gene delivery in cancer and discuss the structures, properties, and various synthesis methods for dendrilers suitable for anticancer drug delivery.
Abstract: The efficacy of anticancer agents is often limited due to treatment-related toxicity, poor pharmacokinetics, and inadequate drug accumulation in the tumor. Advances made in the field of cancer nanomedicine have made it possible to reduce the toxicity, alter the pharmacokinetics and biodistribution, increase site-specific drug delivery, and enhance the efficacy of many therapeutic agents by using nanoparticles as drug carriers. These nanocarriers can be composed of polymers, lipids, proteins, or inorganic materials. Among these delivery systems, dendrimers form a separate class of branched polymer nanoparticles that has shown great promise in cancer drug delivery. In this chapter, we describe the application of dendrimers as nanocarriers for drug and gene delivery in cancer. We discuss the structures, properties, and various synthesis methods for dendrimers suitable for anticancer drug delivery. Further, we describe various types of dendrimers with appropriate examples in different therapeutic modalities of cancer. Recent examples of drug and gene delivery using dendrimers and their advantages are also presented. The application of tumor-targeted delivery systems using dendrimers is described. The chapter concludes with a description of current challenges with dendrimer-based drug delivery and efforts made to bring these promising systems to the forefront of cancer treatment.
References
More filters
TL;DR: The basic characteristics of the EPR effect, particularly the factors involved, are described, as well as its modulation for improving delivery of macromolecular drugs to the tumor.
5,955 citations
TL;DR: This work has revealed unexpected diversity in their biogenesis pathways and the regulatory mechanisms that they access, which has direct implications for fundamental biology as well as disease etiology and treatment.
4,490 citations
TL;DR: This article presents an overview of nanotechnology for the biologist and discusses the attributes of the novel XPclad((c)) nanoparticle formulation that has shown efficacy in treating solid tumors, single dose vaccination, and oral delivery of therapeutic proteins.
2,155 citations
TL;DR: An up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process is provided, and there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials.
Abstract: In this review we provide an up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process. We define nanomedicines as therapeutic or imaging agents which comprise a nanoparticle in order to control the biodistribution, enhance the efficacy, or otherwise reduce toxicity of a drug or biologic. We identified 51 FDA-approved nanomedicines that met this definition and 77 products in clinical trials, with ~40% of trials listed in clinicaltrials.gov started in 2014 or 2015. While FDA approved materials are heavily weighted to polymeric, liposomal, and nanocrystal formulations, there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials. We then provide an overview of the different material categories represented in our search, highlighting nanomedicines that have either been recently approved, or are already in clinical trials. We conclude with some comments on future perspectives for nanomedicines, which we expect to include more actively-targeted materials, multi-functional materials (“theranostics”) and more complicated materials that blur the boundaries of traditional material categories. A key challenge for researchers, industry, and regulators is how to classify new materials and what additional testing (e.g. safety and toxicity) is required before products become available.
1,837 citations
TL;DR: It would be profitable to address a variety of issues and factors that could affect the development of improved targeted drug delivery systems, including nanocarrier, nanovehicle, nanosystem, nanostructure, and other terms used in the literature.
1,603 citations